Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049276 · ClinicalTrials.gov registry record · NA
The Multicentre Selective Lymphadenectomy Trial - 3
A NA study of Cutaneous Melanoma, Stage III, sponsored by Melanoma Institute Australia.
- Recruiting
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 6
- Study locations
NCT07049276 is a NA study of Cutaneous Melanoma, Stage III that is actively recruiting participants, run by Melanoma Institute Australia. The registered enrollment target is 1,500 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT07049276, a NA study of Cutaneous Melanoma, Stage III, is actively recruiting participants, sponsored by Melanoma Institute Australia.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less wound problems \& lymphoedema), an improved quality of life, at a lower healthcare utilisation.
Conditions Studied
Interventions
- PROCEDURE Index lymph node resection
- PROCEDURE Therapeutic lymph node dissection
Study Locations (6)
Other
- San Maria della Misericordia Hospital - Perugia
- The Royal Marsden - London
California
- Cedars-Sinai Medical Centre - Los Angeles
New South Wales
- Melanoma Institute Australia - Wollstonecraft
Ontario
- Sunnybrook Health Sciences Centre - Toronto
Auklnad
- North Shore Hospital - Takapuna
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2040-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07049276
The ClinicalTrials.gov registry entry for NCT07049276 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melanoma Institute Australia, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Melanoma, Stage III appearing as the primary indexed condition, and to 2 interventions - of which Index lymph node resection is the first listed.
NCT07049276 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, California, New South Wales.
Frequently Asked Questions
What is clinical trial NCT07049276 about?
NCT07049276 is a clinical study titled "The Multicentre Selective Lymphadenectomy Trial - 3". The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either s...
What is the current status of trial NCT07049276?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2025-10-01. Estimated completion is 2040-08.
What conditions does trial NCT07049276 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Stage III.
What interventions are being tested in trial NCT07049276?
The interventions under investigation include: Index lymph node resection (PROCEDURE), Therapeutic lymph node dissection (PROCEDURE).
Who is sponsoring clinical trial NCT07049276?
This trial is sponsored by Melanoma Institute Australia, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049276 being conducted?
This trial has 6 study locations across California, New South Wales, Ontario, Auklnad. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma, Stage III
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.